Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of “Buy” from Brokerages

Posted by Brenda Bartman on May 18th, 2026

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been given an average recommendation of “Buy” by the thirteen ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $90.25.

A number of equities research analysts have issued reports on the company. Jefferies Financial Group upped their price objective on Spyre Therapeutics from $47.00 to $85.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Wall Street Zen downgraded Spyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, April 26th. JonesTrading upped their price objective on Spyre Therapeutics from $64.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, April 17th. Raymond James Financial assumed coverage on Spyre Therapeutics in a research report on Monday, April 13th. They set a “strong-buy” rating and a $80.00 price objective on the stock. Finally, Stifel Nicolaus upped their price objective on Spyre Therapeutics from $92.00 to $107.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th.

View Our Latest Research Report on Spyre Therapeutics

Insider Buying and Selling

In other Spyre Therapeutics news, Director Michael Thomas Henderson sold 80,000 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $74.40, for a total transaction of $5,952,000.00. Following the sale, the director directly owned 88,606 shares in the company, valued at $6,592,286.40. This represents a 47.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Cameron Turtle sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $71.37, for a total value of $1,070,550.00. Following the sale, the chief executive officer owned 612,540 shares in the company, valued at approximately $43,716,979.80. This trade represents a 2.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 233,791 shares of company stock valued at $15,757,860. 15.69% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Spyre Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Optimize Financial Inc raised its holdings in shares of Spyre Therapeutics by 1.5% in the fourth quarter. Optimize Financial Inc now owns 25,331 shares of the company’s stock worth $830,000 after buying an additional 364 shares during the period. Mercer Global Advisors Inc. ADV raised its holdings in shares of Spyre Therapeutics by 0.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 106,664 shares of the company’s stock worth $1,788,000 after buying an additional 522 shares during the period. Summit Securities Group LLC purchased a new stake in shares of Spyre Therapeutics in the first quarter worth approximately $28,000. California State Teachers Retirement System raised its holdings in shares of Spyre Therapeutics by 1.8% in the second quarter. California State Teachers Retirement System now owns 33,201 shares of the company’s stock worth $497,000 after buying an additional 603 shares during the period. Finally, AQR Capital Management LLC raised its holdings in shares of Spyre Therapeutics by 4.5% in the fourth quarter. AQR Capital Management LLC now owns 17,820 shares of the company’s stock worth $584,000 after buying an additional 773 shares during the period. 80.39% of the stock is currently owned by hedge funds and other institutional investors.

Spyre Therapeutics Stock Performance

Shares of Spyre Therapeutics stock opened at $74.92 on Wednesday. Spyre Therapeutics has a 12 month low of $13.93 and a 12 month high of $78.80. The stock has a 50 day moving average of $57.47 and a 200 day moving average of $40.88. The firm has a market cap of $6.51 billion, a PE ratio of -36.02 and a beta of 3.12.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.08). As a group, equities research analysts forecast that Spyre Therapeutics will post -2.79 earnings per share for the current fiscal year.

About Spyre Therapeutics

(Get Free Report)

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.